Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study
- PMID: 9694752
- PMCID: PMC28630
- DOI: 10.1136/bmj.317.7155.376
Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study
Abstract
Objective: To compare the cost effectiveness of two possible modifications to the current UK screening programme: shortening the screening interval from three to two years and extending the age of invitation to a final screen from 64 to 69.
Design: Computer simulation model which first simulates life histories for women in the absence of a screening programme for breast cancer and then assesses how these life histories would be changed by introducing different screening policies. The model was informed by screening and cost data from the NHS breast screening programme.
Setting: North West region of England.
Main outcome measures: Numbers of deaths prevented, life years gained, and costs.
Results: Compared with the current breast screening programme both modifications would increase the number of deaths prevented and the number of life years saved. The current screening policy costs 2522 pounds per life year gained; extending the age range of the programme would cost 2612 pounds and shortening the interval 2709 pounds per life year gained. The marginal cost per life year gained of extending the age range of the screening programme is 2990 pounds and of shortening the screening interval is 3545 pounds.
Conclusions: If the budget for the NHS breast screening programme were to allow for two more invitations per woman, substantial mortality reductions would follow from extending the age range screened or reducing the screening interval. The difference between the two policies is so small that either could be chosen.
Comment in
-
Extending the benefits of breast cancer screening. Still hard to know how large the benefits will really be.BMJ. 1998 Aug 8;317(7155):360-1. doi: 10.1136/bmj.317.7155.360. BMJ. 1998. PMID: 9694746 Free PMC article. No abstract available.
-
NHS breast screening programme. Both extended age range and reduced screening interval are needed.BMJ. 1999 Feb 6;318(7180):397-8. doi: 10.1136/bmj.318.7180.397a. BMJ. 1999. PMID: 9933219 Free PMC article. No abstract available.
-
NHS breast screening programme. Growth rate is more important than size.BMJ. 1999 Feb 6;318(7180):398. BMJ. 1999. PMID: 10075472 No abstract available.
-
NHS breast screening programme. Money may be better spent on symptomatic women.BMJ. 1999 Feb 6;318(7180):398. BMJ. 1999. PMID: 10075473 No abstract available.
-
NHS breast screening programme. Modelling is suspect, and results lack confidence intervals.BMJ. 1999 Feb 6;318(7180):398-9. BMJ. 1999. PMID: 10075474 No abstract available.
Similar articles
-
Cost effectiveness of the NHS breast screening programme: life table model.BMJ. 2013 May 9;346:f2618. doi: 10.1136/bmj.f2618. BMJ. 2013. PMID: 23661112 Free PMC article.
-
Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.Acta Oncol. 1997;36 Suppl 9:1-60. Acta Oncol. 1997. PMID: 9143316
-
Breast cancer screening; cost-effective in practice?Eur J Radiol. 2000 Jan;33(1):32-7. doi: 10.1016/s0720-048x(99)00105-9. Eur J Radiol. 2000. PMID: 10674787
-
The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand.Health Policy. 1996 Nov;38(2):101-15. doi: 10.1016/0168-8510(96)00843-3. Health Policy. 1996. PMID: 10160378 Review.
-
Costs of breast cancer and the cost-effectiveness of breast cancer screening.Int J Technol Assess Health Care. 1991;7(4):604-15. doi: 10.1017/s0266462300007169. Int J Technol Assess Health Care. 1991. PMID: 1778705 Review.
Cited by
-
Calibration methods used in cancer simulation models and suggested reporting guidelines.Pharmacoeconomics. 2009;27(7):533-45. doi: 10.2165/11314830-000000000-00000. Pharmacoeconomics. 2009. PMID: 19663525 Free PMC article. Review.
-
Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy.Br J Cancer. 2004 Jan 26;90(2):383-92. doi: 10.1038/sj.bjc.6601520. Br J Cancer. 2004. PMID: 14735181 Free PMC article.
-
Interval cancers in the Dutch breast cancer screening programme.Br J Cancer. 1999 Nov;81(5):912-7. doi: 10.1038/sj.bjc.6690786. Br J Cancer. 1999. PMID: 10555768 Free PMC article.
-
Cost-effectiveness of health-related lifestyle advice delivered by peer or lay advisors: synthesis of evidence from a systematic review.Cost Eff Resour Alloc. 2013 Dec 4;11(1):30. doi: 10.1186/1478-7547-11-30. Cost Eff Resour Alloc. 2013. PMID: 24304826 Free PMC article.
-
Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):718-25. doi: 10.1158/1055-9965.EPI-08-0918. Epub 2009 Mar 3. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19258473 Free PMC article.
References
-
- Forrest APM. Report to the health ministers of England, Wales, Scotland and Northern Ireland by a working group chaired by Sir Patrick Forrest. London: HMSO; 1987.
-
- van Oortmarssen GJ, Habbema JD, van der Maas PJ, de Koning HJ, Collette HJ, Verbeek AL, et al. A model for breast cancer screening. Cancer. 1990;66:1601–1612. - PubMed
-
- de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87:1217–1223. - PubMed
-
- Street AD, Posnett J, Threlfall AG, Woodman CBJ, Twelves E, Friedman EHI, et al. Economic evaluation of proposed changes to the breast screening programme. York: York Health Economics Consortium, University of York; 1996. (Report P20/03.)
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical